© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Associate professor of medicine and neurology, and director, Duke ALS Clinic, Duke Health; and chief, Department of Neurology, Durham Veterans Affairs Medical Center.
May 25, 2021
Key opinion leaders review the study design and mechanisms of action for drugs in ongoing clinical trials and consider the future of amyotrophic lateral sclerosis (ALS).
May 18, 2021
A panel of experts provides insights into recent improvements in clinical trial design in amyotrophic lateral sclerosis (ALS) and discusses implications of recent clinical trial results.
Expert neurologists discuss clinical trial design and FDA approvals for current approaches to pharmacologic management of amyotrophic lateral sclerosis (ALS) and share personal experiences.
May 12, 2021
Key opinion leaders consider the importance of respiratory care in ALS by discussing immunization against respiratory illness as well as the use of non-invasive ventilation.
May 11, 2021
Panelists share approaches for building a dialogue on life sustaining care such as invasive ventilation and discuss the importance of social and cultural factors for patients and families.
May 04, 2021
Expert neurologists discuss the importance of a multidisciplinary approach to the management of symptoms for palliative care in amyotrophic lateral sclerosis (ALS).
A panel of key opinion leaders provides insight into how COVID-19 has continued to impact the diagnosis and management of patients with amyotrophic lateral sclerosis (ALS).
April 27, 2021
Experts in neurology give insight into recent advancements in genetic testing for amyotrophic lateral sclerosis (ALS) and discuss what factors to consider when offering it to patients.
A panel of experts considers the usefulness of diagnostic criteria and disease staging systems for patients with amyotrophic lateral sclerosis (ALS) as entry criteria for clinical trials.
April 20, 2021
Key opinion leaders ALS care comment on best practices when communicating with patients about the unpredictability of disease progression and prognosis.